代谢型谷氨酸受体：精神疾病的潜在药物靶点。
Metabotropic glutamate receptors: potential drug targets for psychiatric disorders.
作者信息
Yasuhara Akito, Chaki Shigeyuki
机构信息
Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd.
出版信息
Open Med Chem J. 2010 May 27;4:20-36. doi: 10.2174/1874104501004020020.
Abstract
Metabotropic glutamate receptors (mGlu receptors) have emerged as new therapeutic targets for psychiatric disorders, such as schizophrenia, depression and anxiety with their regulatory roles in glutamatergic transmissions. To date, several ligands selective for each mGlu receptor have been synthesized, and pharmacological significances of these ligands have been demonstrated in animal models. Among them, mGlu2/3 receptor agonists have been proven to be effective for treating schizophrenia and anxiety disorders in clinical studies, which may prove utilities of mGlu receptor ligands for the treatment of psychiatric disorders. This article reviews recent advances in development of each mGlu receptor ligands and their therapeutic potential.
摘要
代谢型谷氨酸受体（mGlu受体）已成为精神疾病新的治疗靶点，如精神分裂症、抑郁症和焦虑症，因其在谷氨酸能传递中发挥调节作用。迄今为止，已合成了对每种mGlu受体具有选择性的几种配体，并且这些配体的药理学意义已在动物模型中得到证实。其中，mGlu2/3受体激动剂在临床研究中已被证明对治疗精神分裂症和焦虑症有效，这可能证明mGlu受体配体在治疗精神疾病方面的效用。本文综述了每种mGlu受体配体开发的最新进展及其治疗潜力。
相似文献
1
Metabotropic glutamate receptors: potential drug targets for psychiatric disorders.
Open Med Chem J. 2010 May 27;4:20-36. doi: 10.2174/1874104501004020020.
2
Targeting of metabotropic glutamate receptors for the treatment of schizophrenia.
Curr Pharm Des. 2011;17(2):94-102. doi: 10.2174/138161211795049570.
3
Pharmacological profiling of native group II metabotropic glutamate receptors in primary cortical neuronal cultures using a FLIPR.
Neuropharmacology. 2013 Mar;66:264-73. doi: 10.1016/j.neuropharm.2012.05.023. Epub 2012 May 30.
4
The metabotropic glutamate receptors: potential drug targets for the treatment of anxiety disorders?
Eur J Pharmacol. 2014 Jan 15;723:181-4. doi: 10.1016/j.ejphar.2013.12.019. Epub 2013 Dec 18.
5
Group II metabotropic glutamate receptor agonists as a potential drug for schizophrenia.
Eur J Pharmacol. 2010 Aug 10;639(1-3):59-66. doi: 10.1016/j.ejphar.2009.12.041. Epub 2010 Apr 2.
6
Glutamate metabotropic receptors as targets for drug therapy in epilepsy.
Eur J Pharmacol. 2003 Aug 22;476(1-2):3-16. doi: 10.1016/s0014-2999(03)02149-6.
7
Metabotropic glutamate mGlu1 receptor stimulation and blockade: therapeutic opportunities in psychiatric illness.
Eur J Pharmacol. 2010 Aug 10;639(1-3):2-16. doi: 10.1016/j.ejphar.2009.12.043. Epub 2010 Apr 2.
8
Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs.
Pharmacol Ther. 2007 Jul;115(1):116-47. doi: 10.1016/j.pharmthera.2007.04.007. Epub 2007 May 13.
9
New therapeutic frontiers for metabotropic glutamate receptors.
Curr Top Med Chem. 2005;5(9):847-57. doi: 10.2174/1568026054750254.
10
Modulation of group II metabotropic glutamate receptor (mGlu2) elicits common changes in rat and mice sleep-wake architecture.
Eur J Pharmacol. 2009 Jan 28;603(1-3):62-72. doi: 10.1016/j.ejphar.2008.11.018. Epub 2008 Nov 17.
引用本文的文献
1
Insights into the Metabolism, Disposition, and Quantitative Profile of mGlu5 NAM AE90015 with Metabolite Identification and a Novel Integration Method.
Molecules. 2024 Dec 4;29(23):5724. doi: 10.3390/molecules29235724.
2
The Benzoylpiperidine Fragment as a Privileged Structure in Medicinal Chemistry: A Comprehensive Review.
Molecules. 2024 Apr 23;29(9):1930. doi: 10.3390/molecules29091930.
3
Regulation of Glutamatergic Activity via Bidirectional Activation of Two Select Receptors as a Novel Approach in Antipsychotic Drug Discovery.
Int J Mol Sci. 2020 Nov 20;21(22):8811. doi: 10.3390/ijms21228811.
4
Results and evaluation of a first-in-human study of RG7342, an mGlu5 positive allosteric modulator, utilizing Bayesian adaptive methods.
Br J Clin Pharmacol. 2018 Mar;84(3):445-455. doi: 10.1111/bcp.13466. Epub 2017 Dec 18.
5
The Role of Metabotropic Glutamate Receptor Genes in Schizophrenia.
Curr Neuropharmacol. 2016;14(5):540-50. doi: 10.2174/1570159x13666150514232745.
6
Valproic Acid Influences MTNR1A Intracellular Trafficking and Signaling in a β-Arrestin 2-Dependent Manner.
Mol Neurobiol. 2016 Mar;53(2):1237-1246. doi: 10.1007/s12035-014-9085-y. Epub 2015 Jan 24.
7
Quinoline derivatives: candidate drugs for a class B G-protein coupled receptor, the calcitonin gene-related peptide receptor, a cause of migraines.
CNS Neurol Disord Drug Targets. 2014;13(7):1130-9. doi: 10.2174/1871527313666140917111341.
8
Lifelong CRF overproduction is associated with altered gene expression and sensitivity of discrete GABA(A) and mGlu receptor subtypes.
Psychopharmacology (Berl). 2012 Feb;219(3):897-908. doi: 10.1007/s00213-011-2423-0. Epub 2011 Aug 11.
9
Activation of group II metabotropic glutamate receptors inhibits the discriminative stimulus effects of alcohol via selective activity within the amygdala.
Neuropsychopharmacology. 2011 Oct;36(11):2328-38. doi: 10.1038/npp.2011.121. Epub 2011 Jul 6.
10
Glutamatergic drive of the dorsal raphe nucleus.
J Chem Neuroanat. 2011 Jul;41(4):247-55. doi: 10.1016/j.jchemneu.2011.04.004. Epub 2011 Apr 27.
本文引用的文献
1
Dose-dependent effect of CDPPB, the mGluR5 positive allosteric modulator, on recognition memory is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampus.
Neuropharmacology. 2009 Oct-Nov;57(5-6):531-8. doi: 10.1016/j.neuropharm.2009.07.022. Epub 2009 Jul 21.
2
Unique antipsychotic activities of the selective metabotropic glutamate receptor 1 allosteric antagonist 2-cyclopropyl-5-[1-(2-fluoro-3-pyridinyl)-5-methyl-1H-1,2,3-triazol-4-yl]-2,3-dihydro-1H-isoindol-1-one.
J Pharmacol Exp Ther. 2009 Jul;330(1):179-90. doi: 10.1124/jpet.109.151118. Epub 2009 Apr 9.
3
mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning.
Neuropsychopharmacology. 2009 Aug;34(9):2057-71. doi: 10.1038/npp.2009.30. Epub 2009 Mar 18.
4
Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition.
Behav Pharmacol. 2009 Feb;20(1):56-66. doi: 10.1097/FBP.0b013e3283242f57.
5
Endogenous serotonin and serotonin2C receptors are involved in the ability of M100907 to suppress cortical glutamate release induced by NMDA receptor blockade.
J Neurochem. 2009 Jan;108(2):521-32. doi: 10.1111/j.1471-4159.2008.05789.x. Epub 2008 Nov 17.
6
ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities.
J Pharmacol Exp Ther. 2008 Dec;327(3):827-39. doi: 10.1124/jpet.108.136580. Epub 2008 Aug 27.
7
Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonist in rodents: detailed investigations with a selective allosteric metabotropic glutamate receptor 1 antagonist, FTIDC [4-[1-(2-fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide].
J Pharmacol Exp Ther. 2008 Aug;326(2):577-86. doi: 10.1124/jpet.108.138107. Epub 2008 May 16.
8
Interaction of N-methyl-D-aspartate and group 5 metabotropic glutamate receptors on behavioral flexibility using a novel operant set-shift paradigm.
Behav Pharmacol. 2008 May;19(3):225-34. doi: 10.1097/FBP.0b013e3282feb0ac.
9
Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039).
J Pharmacol Exp Ther. 2008 Jul;326(1):209-17. doi: 10.1124/jpet.108.136861. Epub 2008 Apr 18.
10
Attenuation of ketamine-evoked behavioral responses by mGluR5 positive modulators in mice.
Psychopharmacology (Berl). 2008 May;198(1):141-8. doi: 10.1007/s00213-008-1103-1. Epub 2008 Mar 3.
Zotero 插件